PixarBio Corporation has announced that we will stay focused on our NeuroRelease Pain platform and continue to drive  non-opiate non addictive morphine replacement to market with FDA approval expected between the end of 2018 and early 2019.

PixarBio has an IP portfolio covering pain, spinal cord injury, and epilepsy and we believe that we will become future market leaders with our existing, and growing PixarBio patent and IP portfolio for various drug delivery systems.

“On behalf of the shareholders and Board of Directors of PixarBio we withdraw our offer for InVivo Therapeutics Corp for reasons related to management credibility and competence, corporate governance and IP control”. For more information: The Story behind PixarBio’s Termination of the InVivo Therapeutics Deal.